The global medical technology and healthcare technology sectors are undergoing a profound structural realignment, shifting from post-pandemic volume driven consolidation toward highly disciplined portfolio design. Corporate divestitures, spin-offs and carve-outs have become primary mechanisms for multinational healthtech organisations seeking to optimise operating margins, reduce debt and redeploy capital toward high-growth, high-margin clinical categories. Driven by macroeco

The consolidation of GHO Capital and CBC Group represents a notable evolution in the alternative asset management landscape, characterised by the rise of "mega-specialist" managers. This transaction also highlights the strategic role of technology and artificial intelligence (AI) as critical tools for value creation and operational efficiency in the life sciences sector. As noted by the executive leadership, the integration of AI applications into drug discovery, diagnostic i